Shilpa Medicare Limited (SHILPAMED.BO)
INR 643.55
(5.66%)
INR 643.55
(5.66%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.36 Billion INR | 1515.18% |
| 2022 | -96.54 Million INR | -108.23% |
| 2021 | 1.17 Billion INR | -2.96% |
| 2020 | 1.2 Billion INR | -28.74% |
| 2019 | 1.69 Billion INR | 63.89% |
| 2018 | 1.03 Billion INR | 5.62% |
| 2017 | 979.58 Million INR | -27.84% |
| 2016 | 1.35 Billion INR | -1.87% |
| 2015 | 1.38 Billion INR | 23.54% |
| 2014 | 1.11 Billion INR | 12.99% |
| 2013 | 990.97 Million INR | 68.14% |
| 2012 | 589.37 Million INR | 7.88% |
| 2011 | 546.34 Million INR | -15.95% |
| 2010 | 650.05 Million INR | 2.15% |
| 2009 | 636.37 Million INR | 180.02% |
| 2008 | 227.25 Million INR | 50.62% |
| 2007 | 150.88 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 464.91 Million INR | 7.04% |
| 2023 Q1 | 211.73 Million INR | 68.91% |
| 2023 Q3 | 392.35 Million INR | 20.7% |
| 2023 FY | 1.36 Billion INR | 1515.18% |
| 2023 Q4 | 434.33 Million INR | 10.7% |
| 2023 Q2 | 325.07 Million INR | 53.53% |
| 2022 Q2 | -111.1 Million INR | -500.36% |
| 2022 Q4 | 125.35 Million INR | 73.9% |
| 2022 FY | -96.54 Million INR | -108.23% |
| 2022 Q1 | -18.5 Million INR | -103.6% |
| 2022 Q3 | 72.08 Million INR | 164.88% |
| 2021 FY | 1.17 Billion INR | -2.96% |
| 2021 Q2 | 339.8 Million INR | 138.48% |
| 2021 Q1 | 142.48 Million INR | 29.84% |
| 2021 Q3 | 244.38 Million INR | -28.08% |
| 2021 Q4 | 513.85 Million INR | 110.26% |
| 2020 Q3 | 153.84 Million INR | -76.39% |
| 2020 FY | 1.2 Billion INR | -28.74% |
| 2020 Q1 | 582.82 Million INR | 82.18% |
| 2020 Q2 | 651.58 Million INR | 11.8% |
| 2020 Q4 | 109.73 Million INR | -28.67% |
| 2019 Q4 | 319.9 Million INR | -52.05% |
| 2019 Q2 | 624.8 Million INR | 205.08% |
| 2019 FY | 1.69 Billion INR | 63.89% |
| 2019 Q1 | 204.8 Million INR | -33.81% |
| 2019 Q3 | 667.14 Million INR | 6.78% |
| 2018 Q2 | 276.08 Million INR | -36.33% |
| 2018 FY | 1.03 Billion INR | 5.62% |
| 2018 Q3 | 180.73 Million INR | -34.54% |
| 2018 Q1 | 433.65 Million INR | 3.47% |
| 2018 Q4 | 309.4 Million INR | 71.19% |
| 2017 FY | 979.58 Million INR | -27.84% |
| 2017 Q3 | 221.77 Million INR | -51.82% |
| 2017 Q2 | 460.26 Million INR | 47.51% |
| 2017 Q1 | 312.02 Million INR | -44.66% |
| 2017 Q4 | 419.1 Million INR | 88.98% |
| 2016 Q1 | 225.08 Million INR | -56.15% |
| 2016 FY | 1.35 Billion INR | -1.87% |
| 2016 Q4 | 563.84 Million INR | 105.61% |
| 2016 Q3 | 274.23 Million INR | -45.79% |
| 2016 Q2 | 505.91 Million INR | 124.77% |
| 2015 Q4 | 513.27 Million INR | 35.08% |
| 2015 FY | 1.38 Billion INR | 23.54% |
| 2015 Q1 | 230.92 Million INR | -30.33% |
| 2015 Q2 | 369.44 Million INR | 59.98% |
| 2015 Q3 | 379.97 Million INR | 2.85% |
| 2014 Q2 | 247.54 Million INR | -0.97% |
| 2014 FY | 1.11 Billion INR | 12.99% |
| 2014 Q4 | 331.44 Million INR | 13.91% |
| 2014 Q3 | 290.97 Million INR | 17.54% |
| 2014 Q1 | 249.98 Million INR | -15.48% |
| 2013 Q2 | 196.09 Million INR | -3.46% |
| 2013 FY | 990.97 Million INR | 68.14% |
| 2013 Q4 | 295.75 Million INR | -0.11% |
| 2013 Q3 | 296.09 Million INR | 51.0% |
| 2013 Q1 | 203.12 Million INR | 29.56% |
| 2012 FY | 589.37 Million INR | 7.88% |
| 2012 Q2 | 157.52 Million INR | 11.22% |
| 2012 Q3 | 133.43 Million INR | -15.29% |
| 2012 Q1 | 141.63 Million INR | -28.91% |
| 2012 Q4 | 156.78 Million INR | 17.5% |
| 2011 FY | 546.34 Million INR | -15.95% |
| 2011 Q1 | 132.28 Million INR | 0.0% |
| 2011 Q4 | 199.22 Million INR | 128.48% |
| 2011 Q3 | 87.19 Million INR | -12.5% |
| 2011 Q2 | 99.65 Million INR | -24.66% |
| 2010 FY | 650.05 Million INR | 2.15% |
| 2009 FY | 636.37 Million INR | 180.02% |
| 2008 FY | 227.25 Million INR | 50.62% |
| 2007 FY | 150.88 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 76.272% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 96.763% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 84.784% |
| Granules India Limited | 6.81 Billion INR | 79.957% |
| Indoco Remedies Limited | 1.29 Billion INR | -5.704% |
| Achyut Healthcare Limited | 4.43 Million INR | -30685.759% |
| Ajanta Pharma Limited | 19.67 Billion INR | 93.057% |
| Alkem Laboratories Limited | 19.46 Billion INR | 92.98% |
| Alpa Laboratories Limited | 184.49 Million INR | -640.539% |
| Brooks Laboratories Limited | 14.44 Million INR | -9361.717% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | 20.45% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -10.989% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 97.983% |
| Eris Lifesciences Limited | 5.18 Billion INR | 73.633% |
| FDC Limited | 2.98 Billion INR | 54.247% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 78.988% |
| Gufic Biosciences Limited | 1.32 Billion INR | -2.734% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 69.093% |
| Ipca Laboratories Limited | 7.98 Billion INR | 82.88% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -168.882% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 999.118% |
| Lasa Supergenerics Limited | -458 Million INR | 398.309% |
| Laurus Labs Limited | 3.94 Billion INR | 65.399% |
| Lupin Limited | 28.04 Billion INR | 95.128% |
| Mankind Pharma Limited | 21.51 Billion INR | 93.651% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -1262.185% |
| Megasoft Limited | -121.1 Million INR | 1228.181% |
| NATCO Pharma Limited | 25.96 Billion INR | 94.737% |
| Piramal Pharma Limited | 4.55 Billion INR | 70.018% |
| RPG Life Sciences Limited | 2.29 Billion INR | 40.397% |
| Sigachi Industries Limited | 1.47 Billion INR | 7.302% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 98.69% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 70.348% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -448.151% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | -139.816% |
| Windlas Biotech Limited | 1.29 Billion INR | -5.188% |
| ZIM Laboratories Limited | 253.82 Million INR | -438.265% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 96.831% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 133.202% |
| Divi's Laboratories Limited | 33.08 Billion INR | 95.87% |
| Hester Biosciences Limited | 364.81 Million INR | -274.516% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 50.959% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -198.61% |
| Bal Pharma Limited | 233.9 Million INR | -484.104% |
| Strides Pharma Science Limited | 5.22 Billion INR | 73.855% |
| Venus Remedies Limited | 534.65 Million INR | -155.545% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 56.323% |
| Nectar Lifesciences Limited | 923.8 Million INR | -47.896% |
| Aarti Drugs Limited | 7.14 Billion INR | 80.888% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | 14.437% |
| Suven Life Sciences Limited | -1.22 Billion INR | 211.458% |
| Ind-Swift Limited | 1.22 Billion INR | -11.445% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 90.434% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 135.461% |
| Themis Medicare Limited | 392.58 Million INR | -248.016% |
| Hikal Limited | 32.11 Million INR | -4154.974% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 94.607% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | -118.08% |
| Wockhardt Limited | -670 Million INR | 303.921% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 73.67% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -14965.798% |
| Neuland Laboratories Limited | 5.31 Billion INR | 74.309% |
| Morepen Laboratories Limited | 4.17 Billion INR | 67.266% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -556.704% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -4875.861% |